

**REMARKS**

**Status of the Claims**

Claims 1, 6-9, 14-21 and 27 have been cancelled. Claims 2, 3, 10-13, 23-26, and 28 have been amended. Claims 29-33 have been added. Accordingly, Claims 2-5, 10-13, 22-26, and 28-33 are pending.

**Discussion of the Amendments**

Claims 3, 10-13, 26, and 28 have been amended to eliminate multiple dependencies. Claims 23 and 25 have been amended from dependent to independent form. Claim 24 has been amended to depend from claim 23.

Claim 2 has been amended to add a recitation that the isolated peptide has “at least 10 synthetic amino acids” and exhibits “paralytic activity.” Support for the amendment to claim 2 is found, for example, on page 8, lines 1-3, page 5, line 25 to page 6, line 1 and page 15, lines 17-21.

Claims 29-32 have been added. Support for new claim 29 is found, for example on page 14, lines 15-19. Support for new claim 30 is found, for example, on page 10, lines 1-3. Support for new claim 31 is found, for example, in originally filed claim 2. Support for new claims 32 and 33 is found, for example on page 15, lines 17-21.

No new matter has been added.

In re application of John M. Stewart, et al.  
Application No. 10/716,314

S&L File P26,473-A USA  
August 21, 2006  
Page 6

An early and favorable Action is requested.

Respectfully submitted,

/Marc S. Segal/

Marc S. Segal  
Reg. No. 40,163

SYNNESTVEDT & LECHNER LLP  
2600 Aramark Tower  
1101 Market Street  
Philadelphia, PA 19107-2950  
Telephone - (215) 923-4466  
Facsimile - (215) 923-2189

S:\B\BERESKIN & PARR\Patents\P26473-A USA\PTO\Supplemental Preliminary Amendment.doc